Autologous intracoronary mononuclear bone marrow cell transplantation in chronic ischemic cardiomyopathy in humans

Kuethe, Friedhelm; Richartz, Barbara M.; Kasper, Christoph; Sayer, Herbert G.; Hoeffken, Klaus; Werner, Gerald S.; Figulla, Hans R.

doi:10.1016/j.ijcard.2004.12.007

Cited by 44 publications

(36 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This result is consistent with the finding of a previous study in which no therapeutic effect was obtained by cell implantation for chronic ischemic disease. 29 Agreeing well with our in vitro data, the results of our in vivo studies also indicated that the microenvironment of acute ischemic tissues was more conducive to the survival of implanted BMCs and the improvement of blood flow than that of chronic ischemic tissue, suggesting that it would be more beneficial for cell-based therapeutic angiogenesis. Because the microenvironment of acute ischemic tissue is complicated by many increased cytokines and by oxidative stress, [15][16][17] further studies should be done on the effects of cytokine inhibition with neutralizing antibodies on the survival of implanted cells in the acute ischemic tissue, in order to identify the important key cytokines that promote the survival and angiogenic potency of BMCs.…”

Section: Discussionsupporting

confidence: 78%

Transient Increase of Cytokines in the Acute Ischemic Tissue is Beneficial to Cell-Based Therapeutic Angiogenesis

Qin

Kubo

et al. 2008

Circ J

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 78%

Transient Increase of Cytokines in the Acute Ischemic Tissue is Beneficial to Cell-Based Therapeutic Angiogenesis

Qin

Kubo

et al. 2008

Circ J

View full text Add to dashboard Cite

“…[2][3][4] However, therapeutic efficacy of this approach for treating post-MI chronic heart failure (HF) has not been fully established. [5][6][7][8][9][10][11] In addition, arrhythmia occurrence, which has been identified as a critical complication of skeletal myoblast injection, 12 has not been fully studied in the case of BM cell injection. Previous clinical studies reported rare incidences of arrhythmia after intramyocardial 5,8,9 and antegrade intracoronary 6,7,10,11 injection of BM cells; however, patients in these studies were prescribed antiarrhythmic drugs such as ␤-blockers, [5][6][7][8][9]11 which could mask arrhythmogenicity of the treatment.…”

mentioning

confidence: 99%

“…In addition, arrhythmia occurrence in these patients might not be adequately examined by appropriate continuous monitoring. 5,[7][8][9][10][11] Elucidating these issues by appropriate laboratory investigations is now an urgent requisite for the further progress of clinical application of the treatment.…”

mentioning

confidence: 99%

Direct Intramyocardial But Not Intracoronary Injection of Bone Marrow Cells Induces Ventricular Arrhythmias in a Rat Chronic Ischemic Heart Failure Model

et al. 2007

View full text Add to dashboard Cite

Background-Therapeutic efficacy of bone marrow (BM) cell injection for treating ischemic chronic heart failure has not been established. In addition, experimental data are lacking on arrhythmia occurrence after BM cell injection. We hypothesized that therapeutic efficacy and arrhythmia occurrence induced by BM cell injection may be affected by the cell delivery route. Methods and Results-Three weeks after left coronary artery ligation, wild-type female rats were injected with 1ϫ10

show abstract

“…There also exist a few studies done by using intracoronary infusion method in ischemic cardiomyopathy patients (Kuethe et al 2005;Assmus et al 2007). Cell retention might be expected to be limited after intracoronary delivery into chronically infarcted myocardium, due to the limited blood supply faced by transplanted cells or the environmental factors that affect homing or transdifferentiating into vascular cells and cardiomyocytes.…”

Section: Discussionmentioning

confidence: 99%

Intracoronary Stem Cell Infusion in Heart Transplant Candidates

Tayyareci

Umman

Sezer

et al. 2007

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

The stem cell transplantation is emerging as a potential therapeutic modality for patients with heart failure. It has been demonstrated that intracoronary stem cell transplantation had beneficial effects on left ventricular perfusion and contractile functions. We hypothesized that patients with end-stage ischemic cardiomyopathy, who are candidates for heart transplantation, could also benefit from autologous intracoronary stem cell transplantation. We performed a prospective, openlabeled study in 10 patients with end-stage ischemic cardiomyopathy, who were on the waiting list for heart transplantation. Each patient received bone marrow-derived mononuclear cell infusion via balloon catheter in the target vessel, which had been revascularized by percutaneous intervention and was patent before the procedure. Clinical and laboratory evaluations, a treadmill exercise test, echocardiography, and single photon emission tomography (SPECT) were performed to the patients at baseline and 6 months after stem cell infusion. At 6-month follow-up of the eight patients who were able to complete the study, we revealed a significant increase in ejection fraction (from 30.0 ± 6.6% to 36.2 ± 7.3%; p = 0.001) in echocardiographic evaluation. SPECT evaluation also displayed a reduction in infarct area (50.4 ± 16.1% to 44.1 ± 12.5%; p = 0.003). Both myocardial oxygen consumption ( p = 0.001) and metabolic equivalents ( p = 0.001) were significantly increased at 6-month follow-up. These results demonstrate that intracoronary stem cell transplantation ameliorates heart failure symptoms and improves left ventricular function and perfusion. Therefore intracoronary stem cell transplantation may be used as an alternative treatment option for heart transplant candidates. cellular cardiomyoplasty; heart transplant candidates; intracoronary infusion; stem cells; ischemic cardiomyopathy © 2007 Tohoku University Medical PressCongestive heart failure (CHF) of ischemic origin remains to be a major clinical problem despite major advances in medical and surgical treatment of patients with myocardial infarction (MI) both during acute and chronic phases. In the acute setting of MI, revascularization procedures,

show abstract

Autologous intracoronary mononuclear bone marrow cell transplantation in chronic ischemic cardiomyopathy in humans

Cited by 44 publications

References 29 publications

Transient Increase of Cytokines in the Acute Ischemic Tissue is Beneficial to Cell-Based Therapeutic Angiogenesis

Transient Increase of Cytokines in the Acute Ischemic Tissue is Beneficial to Cell-Based Therapeutic Angiogenesis

Direct Intramyocardial But Not Intracoronary Injection of Bone Marrow Cells Induces Ventricular Arrhythmias in a Rat Chronic Ischemic Heart Failure Model

Intracoronary Stem Cell Infusion in Heart Transplant Candidates

Contact Info

Product

Resources

About